S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   304.00 (+0.18%)
AAPL   123.17 (+0.37%)
MSFT   215.15 (-0.49%)
FB   287.52 (+0.34%)
GOOGL   1,827.63 (+1.80%)
AMZN   3,204.07 (-0.50%)
TSLA   566.00 (-3.21%)
NVDA   541.64 (+1.13%)
BABA   261.74 (-0.86%)
CGC   27.91 (+4.73%)
GE   10.40 (+2.46%)
MU   69.10 (+3.01%)
AMD   93.62 (+1.07%)
T   29.09 (+0.76%)
NIO   47.47 (+4.65%)
F   9.19 (-0.54%)
ACB   11.05 (+13.33%)
NFLX   503.43 (-0.23%)
BA   224.25 (+5.28%)
GILD   61.14 (+0.03%)
DIS   153.79 (+2.91%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   304.00 (+0.18%)
AAPL   123.17 (+0.37%)
MSFT   215.15 (-0.49%)
FB   287.52 (+0.34%)
GOOGL   1,827.63 (+1.80%)
AMZN   3,204.07 (-0.50%)
TSLA   566.00 (-3.21%)
NVDA   541.64 (+1.13%)
BABA   261.74 (-0.86%)
CGC   27.91 (+4.73%)
GE   10.40 (+2.46%)
MU   69.10 (+3.01%)
AMD   93.62 (+1.07%)
T   29.09 (+0.76%)
NIO   47.47 (+4.65%)
F   9.19 (-0.54%)
ACB   11.05 (+13.33%)
NFLX   503.43 (-0.23%)
BA   224.25 (+5.28%)
GILD   61.14 (+0.03%)
DIS   153.79 (+2.91%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   304.00 (+0.18%)
AAPL   123.17 (+0.37%)
MSFT   215.15 (-0.49%)
FB   287.52 (+0.34%)
GOOGL   1,827.63 (+1.80%)
AMZN   3,204.07 (-0.50%)
TSLA   566.00 (-3.21%)
NVDA   541.64 (+1.13%)
BABA   261.74 (-0.86%)
CGC   27.91 (+4.73%)
GE   10.40 (+2.46%)
MU   69.10 (+3.01%)
AMD   93.62 (+1.07%)
T   29.09 (+0.76%)
NIO   47.47 (+4.65%)
F   9.19 (-0.54%)
ACB   11.05 (+13.33%)
NFLX   503.43 (-0.23%)
BA   224.25 (+5.28%)
GILD   61.14 (+0.03%)
DIS   153.79 (+2.91%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   304.00 (+0.18%)
AAPL   123.17 (+0.37%)
MSFT   215.15 (-0.49%)
FB   287.52 (+0.34%)
GOOGL   1,827.63 (+1.80%)
AMZN   3,204.07 (-0.50%)
TSLA   566.00 (-3.21%)
NVDA   541.64 (+1.13%)
BABA   261.74 (-0.86%)
CGC   27.91 (+4.73%)
GE   10.40 (+2.46%)
MU   69.10 (+3.01%)
AMD   93.62 (+1.07%)
T   29.09 (+0.76%)
NIO   47.47 (+4.65%)
F   9.19 (-0.54%)
ACB   11.05 (+13.33%)
NFLX   503.43 (-0.23%)
BA   224.25 (+5.28%)
GILD   61.14 (+0.03%)
DIS   153.79 (+2.91%)
Log in
NASDAQ:BMRA

Biomerica Stock Forecast, Price & News

$6.79
+0.24 (+3.66 %)
(As of 12/2/2020 03:58 PM ET)
Add
Compare
Today's Range
$6.63
Now: $6.79
$6.80
50-Day Range
$5.40
MA: $6.29
$7.83
52-Week Range
$2.05
Now: $6.79
$23.39
Volume1,614 shs
Average Volume781,838 shs
Market Capitalization$79.80 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.73
Biomerica, Inc., a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy that is designed to allow physicians to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms; Helicobacter pylori products; and develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BMRA
CUSIPN/A
Phone949-645-2111
Employees65

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.69 million
Book Value$1.43 per share

Profitability

Net Income$-2,340,000.00

Miscellaneous

Market Cap$79.80 million
Next Earnings Date1/20/2021 (Estimated)
OptionableNot Optionable
$6.79
+0.24 (+3.66 %)
(As of 12/2/2020 03:58 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BMRA News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Biomerica (NASDAQ:BMRA) Frequently Asked Questions

How has Biomerica's stock been impacted by COVID-19?

Biomerica's stock was trading at $2.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BMRA shares have increased by 131.4% and is now trading at $6.71.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Biomerica?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomerica in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Biomerica
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Biomerica?

Wall Street analysts have given Biomerica a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Biomerica wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Biomerica's next earnings date?

Biomerica is scheduled to release its next quarterly earnings announcement on Wednesday, January 20th 2021.
View our earnings forecast for Biomerica
.

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) announced its earnings results on Thursday, October, 15th. The company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.06. The company earned $1.14 million during the quarter, compared to the consensus estimate of $1.09 million. Biomerica had a negative net margin of 52.42% and a negative return on equity of 40.08%.
View Biomerica's earnings history
.

What price target have analysts set for BMRA?

2 brokers have issued 12 month price objectives for Biomerica's shares. Their forecasts range from $11.00 to $13.00. On average, they anticipate Biomerica's stock price to reach $11.67 in the next twelve months. This suggests a possible upside of 73.9% from the stock's current price.
View analysts' price targets for Biomerica
.

Who are some of Biomerica's key competitors?

What other stocks do shareholders of Biomerica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ), Ampio Pharmaceuticals (AMPE), OPKO Health (OPK), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Co-Diagnostics (CODX), FuelCell Energy (FCEL) and Trevena (TRVN).

Who are Biomerica's key executives?

Biomerica's management team includes the following people:
  • Mr. Zackary S. Irani, Chairman & CEO (Age 54, Pay $136.61k)
  • Mr. Allen C. Barbieri, Exec. Vice-Chairman (Age 62, Pay $7.5k)
  • Ms. Janet Moore, Treasurer, Sec. & Director (Age 69, Pay $109.11k)
  • Mr. Steven Sloan, Chief Financial Officer (Age 50)

What is Biomerica's stock symbol?

Biomerica trades on the NASDAQ under the ticker symbol "BMRA."

Who are Biomerica's major shareholders?

Biomerica's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Squarepoint Ops LLC (0.16%) and Emerald Advisers LLC (0.09%). Company insiders that own Biomerica stock include Catherine Coste and Mark A Sirgo.
View institutional ownership trends for Biomerica
.

Which major investors are buying Biomerica stock?

BMRA stock was bought by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, and Squarepoint Ops LLC.
View insider buying and selling activity for Biomerica
.

How do I buy shares of Biomerica?

Shares of BMRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biomerica's stock price today?

One share of BMRA stock can currently be purchased for approximately $6.71.

How big of a company is Biomerica?

Biomerica has a market capitalization of $78.86 million and generates $6.69 million in revenue each year. The company earns $-2,340,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. Biomerica employs 65 workers across the globe.

What is Biomerica's official website?

The official website for Biomerica is www.biomerica.com.

How can I contact Biomerica?

Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company can be reached via phone at 949-645-2111.

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.